Discontinuous Schedule of Bevacizumab in Colorectal Cancer Induces Accelerated Tumor Growth and Phenotypic Changes
-
Published:2018-04
Issue:2
Volume:11
Page:406-415
-
ISSN:1936-5233
-
Container-title:Translational Oncology
-
language:en
-
Short-container-title:Translational Oncology
Author:
Becherirat Selma,
Valamanesh Fatemeh,
Karimi Mojgan,
Faussat Anne-Marie,
Launay Jean-Marie,
Pimpie Cynthia,
Therwath Amu,
Pocard MarcORCID
Funder
Fondation de l’avenir
Fondation de France
Subject
Cancer Research,Oncology
Reference46 articles.
1. Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis;Stoeltzing;Ann Surg Oncol,2003
2. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004
3. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane;Burstein;J Clin Oncol Off J Am Soc Clin Oncol,2008
4. Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery;Cacheux;Ann Oncol Off J Eur Soc Med Oncol,2008
5. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis;Johannsen;Eur Urol,2009
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献